(NASDAQ: FATE) Fate Therapeutics's forecast annual revenue growth rate of 92.56% is forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 37.04%, and it is also forecast to beat the US market's average forecast revenue growth rate of 9.92%.
Fate Therapeutics's revenue in 2024 is $63,533,000.On average, 6 Wall Street analysts forecast FATE's revenue for 2024 to be $261,292,359, with the lowest FATE revenue forecast at $148,856,262, and the highest FATE revenue forecast at $396,950,032. On average, 1 Wall Street analysts forecast FATE's revenue for 2025 to be $4,033,508,513, with the lowest FATE revenue forecast at $4,033,508,513, and the highest FATE revenue forecast at $4,033,508,513.
In 2027, FATE is forecast to generate $2,928,498,861 in revenue, with the lowest revenue forecast at $2,928,498,861 and the highest revenue forecast at $2,928,498,861.